Despite a quarterly revenue dip, Fulcrum Therapeutics Inc (FULC) strengthens its cash position and advances key programs, ...

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar ...

On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral ...

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...

A meeting of the CDC's Advisory Committee on Immunization Practices (ACIP), which provides guidance on recommended vaccines and for which populations, scheduled for later this month has been postponed ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...